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ABSTRACT:
To increase the safety and possibly efficacy of HIV-1 derived lentivectors (LVs) as 
an anti-cancer vaccine, we recently developed the Nanobody (Nb) display technology 
to target LVs to antigen presenting cells (APCs). In this study, we extend these 
data with exclusive targeting of LVs to conventional dendritic cells (DCs), which are 
believed to be the main cross-presenting APCs for the induction of a TH1-conducted 
antitumor immune response. The immunogenicity of these DC-subtype targeted LVs 
was compared to that of broad tropism, general APC-targeted and non-infectious 
LVs. Intranodal immunization with ovalbumin encoding LVs induced proliferation 
of antigen specific CD4+ T cells, irrespective of the LVs’ targeting ability. However, 
the cytokine secretion profile of the restimulated CD4+ T cells demonstrated that 
general APC targeting induced a similar TH1-profile as the broad tropism LVs while 
transduction of conventional DCs alone induced a similar and less potent TH1 profile as 
the non-infectious LVs. This observation contradicts the hypothesis that conventional 
DCs are the most important APCs and suggests that the activation of other APCs is 
also meaningful. Despite these differences, all targeted LVs were able to stimulate 
cytotoxic T lymphocytes, be it to a lesser extent than broad tropism LVs. Furthermore 
this induction was shown to be dependent on type I interferon for the targeted and 
non-infectious LVs, but not for broad tropism LVs. Finally we demonstrated that the 
APC-targeted LVs were as potent in therapy as broad tropism LVs and as such deliver 
on their promise as safer and efficacious LV-based vaccines.
INTRODUCTION
Numerous strategies have been developed to 
stimulate the patients’ immune system to reject cancer 
cells. Of these, immunization with ex vivo generated 
dendritic cells (DCs) loaded with tumor-associated 
antigens (TAAs) has shown promise [1–3]. In order to 
perform their stimulatory function, these DCs are further 
activated, for which a multitude of stimuli are available 
[4]. A major question that remains is whether these ex vivo 
generated DCs resemble a specific DC-subset that can be 
found in vivo and linked herewith whether these are the 
best equipped for cancer immunotherapy purposes [5, 6].
Several DC-subsets have been described in mice. 
Simplified, DCs are subdivided in conventional DCs 
(cDCs), plasmacytoid DCs (pDCs) and certain tissue-
specific populations such as Langerhans’ cells (LCs) in the 
epidermis. In addition, cDCs are usually subdivided into 
CD8alfa- and CD8afla+ cDCs [6, 7]. These DC-subsets 
are endowed with distinct functions and it is believed that 
cDCs, in particular CD8alfa+ cDCs are key players in the 
activation of cancer-specific immunity. They produce large 
amounts of IL-12, as such enabling the polarization of 
naive CD4+ T cells towards a T helper 1 (TH1) phenotype 
[8]. This is critical as these TH1 cells have three main 
functions in the anti-cancer immune response: (1) DC 
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licensing, (2) supporting CD8+ cytotoxic T lymphocyte 
(CTL) responses and (3) aiding directly in tumor 
rejection [9]. Moreover, CD8alfa+ cDCs are involved 
in cross-presentation, a critical process in spontaneous 
tumor cell rejection. Although subtle differences exist 
between the human and mouse immune system, it needs 
to be highlighted that the aforementioned DC-subsets 
are also found in humans. Here pDCs are characterized 
by the expression of blood-DC antigen (BDCA) 2 and 
4, whereas cDCs either express BDCA1 (CD1c) or 
BDCA3 (CD141) [6]. Formerly, BDCA3+ cDCs were 
seen as the counterparts of the mouse CD8alfa+ cDCs as 
they efficiently cross-present TAAs to CTLs and as both 
depend on transcription factor BATF3 for their generation 
[10]. However, recently the BDCA1+ cDCs were shown to 
closer resemble mouse CD8alfa+ cDCs in terms of IL-12 
secretion and cross-presentation [11]. Since it remains a 
major challenge to generate ex vivo high numbers of DCs 
that resemble a certain subset, an attractive alternative 
would be to target DC-subsets in vivo.
Various TAA-delivery systems have been 
developed, including autologous and allogeneic tumor 
cell lysates, proteins, peptides, DNA- and mRNA-based 
formulations. In general these are all safe but as no 
intrinsic immunogenic factors are present, the inclusion 
of adjuvants or immunomodulators are crucial for optimal 
DC activation as otherwise tolerance could be induced 
[12]. Recently, the development of particulate delivery 
systems was introduced, in which TAAs are targeted to 
DCs along with adjuvants. These delivery systems have 
been extensively reviewed elsewhere [13]. However, TAA-
derived proteins and peptides have poor pharmacokinetic 
properties and are rapidly cleaved. Moreover, as these are 
exogenous antigens, only cross-presentation can lead to 
MHC I-mediated CTL induction. Therefore the use of 
TAA-encoding plasmid DNA or mRNA would be more 
interesting. 
An attractive way to introduce nucleic acids 
in antigen presenting cells (APCs) is through viral 
transduction. In this regard, lentivectors (LVs) represent 
excellent tools for the delivery of viral RNA to APCs [14]. 
In addition, they ensure persistent transgene expression 
in the transduced APC, which leads to continual antigen 
presentation and immunization [15]. Moreover, LVs are 
intrinsically immunogenic, which leads to activation of 
innate viral sensing pathways such as Toll like receptors 
(TLRs), which consequently leads to the induction of 
strong adaptive immunity [16–18]. In comparative studies 
of in vivo administration of LVs to ex vivo transduced 
DCs, peptide or DNA vaccination strategies, stronger 
TAA-specific immune responses were elicited with 
increased protection to tumor challenge and survival 
when immunization was performed with LVs [19–21]. 
This could be partially explained by the observation that 
cytokine driven DCs are less potent than DCs activated 
through microbial/viral signals in the generation of 
adaptive immunity [22]. Another important advantage 
of LVs is the ease with which their envelope can be 
engineered to alter their tropism. This process is called 
pseudotyping and enables targeting of specific DC-
subsets. The latter is advantageous as it reduces the risk 
of insertional mutagenesis, since proviral DNA is only 
inserted in the genome of terminally differentiated APCs, 
which are short-lived after activation. 
To answer the purpose of DC-subset specific 
targeting, we developed the Nanobody (Nb) display 
technology in which DC-specific Nbs are used as targeting 
moieties. These are inserted in the LV envelope together 
with a truncated version of the vesicular stomatitis virus 
glycoprotein (VSV.GS). This envelope initiates fusion 
after the Nb binds its antigen on the target cell. Previously 
we published the proof-of-principle of this technology in 
which we demonstrated that it is possible to produce Nb 
displaying LVs at high titers and that these allow in vivo 
targeting of APCs [23]. We used Nb DC2.1, which was 
described by De Groeve et al. to recognize a wide range 
of myeloid cells [24]. In the study, they also reported on 
Nb DC1.8, which specifically binds to immature bone 
marrow–derived DCs in vitro. In the present study we 
compared the in vivo transduction profile and immune 
stimulatory potential of broad tropism LVs to non-
infectious BCII10, APC-targeted DC1.8 and DC2.1 
displaying LVs, referred to as VSV.G-, BCII10-, DC1.8- 
and DC2.1-LVs respectively. We report on the possibility 
to exclusively transduce cDCs by DC1.8-LVs while also 
macrophages and pDCs are transduced by DC2.1-LVs. 
This difference in transduction profile was reflected in 
their potential to stimulate both antigen-specific CD8+ 
and CD4+ T cells. Surprisingly, the APC-targeted LVs as 
well as the non-infectious BCII10-LVs showed a similar 
therapeutic potential to VSV.G-LVs but for the former LV-
types, this depended entirely on type I interferon (IFN).
 RESULTS
DC1.8- and DC2.1-LVs target distinct mouse 
APC-subsets 
Recently, we delivered a proof-of-principle on the 
Nb display technology, demonstrating high titer production 
of DC2.1-LVs and their ability to target mouse DCs and 
macrophages in vivo [23]. In this study we additionally 
utilized Nb DC1.8, which was shown to exclusively bind 
immature mouse DCs [24], demonstrating that also DC1.8-
LVs can be produced at high titers (data not shown). 
To compare the transduction profile of DC1.8-LVs 
to that of VSV.G-, BCII10- and DC2.1-LVs in vivo, Thy1.1 
encoding LVs were administered intranodally in C57BL/6 
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mice. Thirty-six hours later, LNs were resected and Thy1.1 
expressing cells characterized by flow cytometry (Figure 
1A), demonstrating that VSV.G-LVs transduced B and T 
cells, macrophages, cDCs and pDCs. In contrast, BCII10-
LVs did not infect these cell types. Importantly, DC1.8-
LVs specifically transduced CD8alfa+ and CD8alfa- cDCs, 
while DC2.1-LVs additionally transduced macrophages 
and pDCs (Figure 1B). In vivo bioluminescence imaging 
was performed at several time points after intranodal 
delivery of FLuc encoding LVs to evaluate the persistence 
of modified cells. Thirty-six hours after administration 
of infectious LVs, expression of FLuc was observed as 
a luminescent signal, while no signal was observed after 
BCII10-LV injection. Luminescence was detectable for 
over 20 days when VSV.G-LVs were administered. In 
contrast, FLuc expression decreased to undetectable levels 
over a period of four days when DC1.8- or DC2.1-LVs 
were used (Figure 1C). 
Immunization with targeted LVs elicits CD8+ T 
lymphocyte responses, be it to a lesser extent than 
immunization with broad tropism LVs
Since CD8+ CTLs play a critical role in the control 
of cancer, we first evaluated the proliferation of CD8+ T 
cells upon immunization with ovalbumin encoding LVs. 
We transferred CD45.2+ OT-I cells to CD45.1+ mice after 
which these were immunized intranodally. Five days 
later, the injected LNs were isolated to evaluate OT-I 
proliferation in flow cytometry. Although proliferation 
of CD8+ T cells was observed in mice immunized with 
BCII10-, DC1.8- or DC2.1-LVs, it did not reach the levels 
observed in mice immunized with VSV.G-LVs (Figure 2A-
B). To further investigate the ability of the targeted LVs to 
elicit functional CD8+ T cell responses, the percentage of 
IFN-gamma+ CD8+ T cells was evaluated by enriching the 
CD45.2+ OT-I cells from the injected LN and spleen, and 
in vitro restimulating them for 72 hours. This experiment 
Figure 1: Targeted transduction of murine APCs in situ. (A) To evaluate Thy1.1 expression in macrophages, cDCs, pDCs, B and 
T cells, LN cells were stained with an anti-Thy1.1 antibody in combination with antibodies directed against CD11b, F4/80, CD11c, B220, 
CD19 and CD3, respectively. (B) To track the transduced LN cells, we administered 15 μl of PBS (mock) or 10E6 TUs of the different 
LV pseudotypes encoding Thy1.1 to the inguinal LN of Thy1.2+ C57BL/6 mice. After 36 hours the injected LNs were isolated and flow 
cytometry was performed on single cell suspensions. The graph summarizes the results of 3 independent experiments as mean ± SEM (n 
= 3, 1 mouse per experiment). (C) To evaluate the transduction profile and kinetics of VSV.G-, BCII10-, DC1.8- and DC2.1-LVs in vivo, 
we injected 10E6 TUs of each LV stock encoding Fluc in the inguinal LN of C57Bl/6 mice. Thirty-six, 72 and 144 hours later, in vivo 
bioluminescence imaging was performed to obtain bioluminescent pseudo-color images superimposed on gray-scale photographs in which 
high luminescence is shown in red and weak luminescence in blue (n = 3, 1 mouse per experiment). The color scale underneath the images 
represents the correlation between the luminescent signal and the absolute amount of counts (light units).
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Figure 3: Intranodal delivery of targeted LVs encoding ovalbumin results in stimulation of cytotoxic ovalbumin specific 
CD8+ T cells and depends entirely on type I IFN. Ovalbumin-specific cytotoxicity of the induced CD8+ T cells was evaluated via 
an in vivo CTL assay. This assay was performed in wild type (A and B) or in IFN type I receptor (IFNAR) ko mice (C), five days after 
intranodal administration of PBS, 5x10E5 TUs VSV.G-, BCII10-, DC1.8- or DC2.1-LVs encoding ovalbumin. Average values of the PBS 
group were substracted from the other values (n = 2, 3 mice per experiment). To evaluate the induction of the innate cytokine TNF-alfa, LNs 
were isolated and placed in culture three hours after they were injected with nothing, PBS, broad tropism, BCII10- or targeted-LVs. Twenty 
hours later, the supernatants of the crushed LNs were screened for the presence of TNF-alfa via ELISA (D) (n=2, 2 mice per experiment).
Figure 2: Intranodal delivery of targeted LVs encoding ovalbumin results in stimulation of ovalbumin-specific CD8+ 
T cells. (A and B) CFSE-labeled OT-I cells were adoptively transferred to C57BL/6 mice one day prior to intranodal administration of 
PBS, 5x10E5 TUs VSV.G-, BCII10-, DC1.8- or DC2.1-LVs encoding ovalbumin. Five days later, LNs were resected, single cell suspensions 
prepared, after which induction of OT-I proliferation was evaluated by flow cytometry. Average values of the PBS group were substracted 
from the other values (n = 3, 2 mice per experiment). (C and D) To recover a reliable amount of CD45.2+ OT-I cells we adoptively transferred 
them to CD45.1+ C57BL/6 mice in which the CD45 marker served as a tool to distinguish which CD8+ T cells were OT-I and which were 
endogenous cells. Five days after immunization, the CD45.2+ fraction was isolated from single cell suspensions, which were subsequently 
restimulated with peptide loaded CD45.1+ splenocytes. After 72 hours, the amount of IFN-gamma + CD8+ T cells was evaluated in flow 
cytometry. Average values of the PBS group were substracted from the other values (n = 2, 2 mice per experiment).
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demonstrated comparable percentages for VSV.G-, DC1.8- 
and DC2.1-LVs while this percentage decreased by half 
for BCII10-LVs (Figure C-D).
The generation of antigen-specific CTLs upon 
immunization with targeted LVs depends on type 
I IFNs 
To evaluate the cytotoxic potential of antigen-
specific CD8+ T cells, we performed an in vivo cytotoxicity 
assay. Although lysis of target cells was observed in mice 
immunized with DC1.8- or DC2.1-LVs, it did not reach 
the levels observed in mice immunized with VSV.G-LVs. 
In addition, as observed in the OT-I proliferation assay, 
immunization with BCII10-LVs also resulted in a certain 
degree of CTL induction (Figure 3A-B). Since pDCs and 
cDCs produce type I IFNs upon infection with VSV.G-
LVs [11, 17], we addressed their role in the induction 
of ovalbumin-specific CTLs. Therefore we performed a 
CTL assay in IFNAR ko mice. The CTL response after 
administration of VSV.G-LVs was not significantly 
affected, whereas the CTL response after administration 
of DC1.8- and DC2.1-LVs as well as BCII10-LVs was 
dependent on type I IFNs (Figure 3C). We hypothesized 
that this might be explained by a different activation of 
the innate immune system by the broad tropism LVs. 
Therefore we evaluated the induction of TNF-alfa as this 
cytokine was previously described to be upregulated upon 
systemic delivery of broad tropism LVs. We observed 
that the production of TNF-alfa was most pronounced 
upon delivery of broad tropism LVs, which strengthens 
the hypothesis that broad tropism and targeted LVs use 
other innate cytokines such as TNF-alfa and type I IFN, 
respectively (Figure 3D). 
Immunization with targeted LVs elicits distinct 
antigen-specific CD4+ T cell responses 
Although CTLs are considered to be the main 
effector cells in anti-tumor immunity, accumulating 
evidence shows that CD4+ T cells are another critical 
component [25, 26]. Therefore, we evaluated the 
expansion of ovalbumin-specific CD4+ T cells upon 
intranodal immunization. Proliferation of OT-II cells 
was strongest after immunization with VSV.G-LVs. 
Notably, the proliferation of OT-II cells was comparable 
after administration of targeted as well as BCII10-LVs 
(Figure 4A). To ensure the specificity of this response, 
we immunized mice with VSV.G-LVs encoding Trp2, 
demonstrating a lack of proliferation. As BCII10-LVs are 
unable to transduce APCs, we hypothesized that these viral 
particles were engulfed via an alternative route, resulting 
in the uptake of the ovalbumin encoding viral genome or 
possibly plasmid DNA or proteins [27]. To evaluate this 
hypothesis, we produced BCII10-LVs encoding Trp2 
in the presence of an ovalbumin encoding eukaryotic 
expression vector. This allows non-specific packaging 
of plasmid DNA and proteins [28]. Subsequently, mice 
Figure 4: Intranodal delivery of targeted as well as BCII10-LVs encoding ovalbumin results in stimulation of ovalbumin-
specific CD4+ T cells. (A-C) CFSE labeled OT-II cells were adoptively transferred one day prior to intranodal administration of PBS or 
5x10E5 TUs of the respective LVs. Five days later, LNs were resected and single cell suspensions prepared to evaluate the induction of OT-
II proliferation by flow cytometry. Average values of the PBS group were substracted from the other values (n = 2, 2 mice per experiment). 
(D) Alternatively, CD4+ T cells were sorted out of the LN-derived single cell suspensions and restimulated with ISQAVHAAHAEINEAGR 
peptide-loaded bone marrow-derived DCs for 48 hours after which supernatants were analyzed for their presence of IFN-gamma, IL-2, 
IL-17, IL-4 and IL-10 in ELISA. Average values of the PBS group were substracted from the other values (n = 3, 4 mice pooled in two 
groups per experiment). More specifically in (A) VSV.G-, BCII10-, DC1.8- or DC2.1-LVs encoding ovalbumin as well as VSV.G-LVs 
encoding Trp2 were injected, in (B) VSV.G- and BCII10-LVs encoding ovalbumin, BCII10-LVs encoding Trp2 or BCII10-LVs encoding 
Trp2 produced in the presence of an ovalbumin encoding plasmid (depicted as + pcDNA3OVA) were administered and in (E) BCII10-LVs 
encoding ovalbumin or Trp2 + pcDNA3OVA and pretreated with 10 U/ml DNase, 100 μg/ml Proteinase K were used or mice were injected 
intraperitoneally 24 hours earlier with 5 ng of the RT inhibitor, Truvada. 
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were immunized with these LVs. Strong proliferation of 
OT-II cells was induced (Figure 4B). Next we scrutinized 
whether this proliferation was due to the presence of 
plasmid DNA or protein. Therefore, mice were immunized 
with LVs that were pre-treated with DNase or proteinase 
K to remove plasmid DNA or proteins respectively. To 
investigate the role of the viral genome, mice were 
injected 24 hours prior to immunization with the RT 
inhibitor Truvada [29]. Proliferation of ovalbumin-specific 
CD4+ OT-II cells was observed in all conditions, except 
when LVs were pre-treated with proteinase K suggesting 
that the presence of protein within the LV stock is the main 
inducer of OT-II proliferation (Figure 4C). 
Since administration of BCII10-LVs was sufficient 
to induce antigen-specific CD4+ T cell proliferation, but 
had only minor effects on CD8+ T cell induction when 
compared to targeted LVs, we addressed which CD4+ T 
cell phenotype was stimulated by the LVs. Therefore we 
evaluated the secretion of cytokines by CD4+ T cells that 
were restimulated in vitro. The CD4+ T cells from mice 
immunized with VSV.G- and DC2.1-LVs induced a similar 
TH1 profile with similar amounts of IFN-gamma, IL-2, and 
IL-10. To our surprise, mice immunized with DC1.8-LVs 
produced less of these cytokines, which made their profile 
similar to the one induced by the BCII10-LVs (Figure 4D). 
Immunization with broad tropism or targeted 
LVs results in similar therapeutic efficacy 
To evaluate the therapeutic potential of the LVs, 
mice bearing E.G7-OVA tumors were immunized twice at 
a seven-day interval. The median survival of mice treated 
with PBS was 14 days while this was prolonged to 19, 
20, 17 and 23 days upon immunization with ovalbumin 
encoding BCII10-, DC1.8-, DC2.1- and VSV.G-LVs 
respectively. Of note, although DC2.1-LVs induced the 
lowest median survival in days, they did show the longest 
dispersion in time with the last mouse surviving till day 32 
(Figure 5).  
DISCUSSION
Targeting APCs is believed to be key to develop safe 
and efficacious LV-based anti-cancer vaccines [30–34]. 
Here we report on the Nb display technology to target LVs 
to mouse APC-subsets. 
We compared the transduction profile of broad 
tropism LVs to LVs harboring the β-lactamase-specific 
Nb BCII10, or the APC-targeting Nbs DC1.8 or DC2.1. 
We chose to deliver these LVs to the LN as this organ 
contains a relative high number of DCs [35] and as it 
has been described that lower antigen doses are required 
to achieve similar immune responses [36]. Tracking the 
transduced cells within the LN demonstrated the exclusive 
Figure 5: Intranodal vaccination of targeted LVs encoding ovalbumin results in prolonged survival in an E.G7-OVA 
model. To evaluate the therapeutic potential of the targeted LVs, C57BL/6 mice were challenged on day 0 with 3x10E5 E.G7-OVA cells. 
When palpable tumors were present mice were immunized intranodally with PBS or 10E6 TUs VSV.G-, BCII10-, DC1.8- or DC2.1-LVs 
encoding ovalbumin. Seven days later, the treatment was repeated. Tumor growth and survival were examined every two days. The results 
shown are representative for two independent experiments (n = 2, 4 mice per experiment).
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transduction of cDCs by DC1.8-LVs, while DC2.1-LVs 
transduced cDCs, pDCs and macrophages. Of note, both 
the CD8alfa+ and CD8alfa- cDC fractions were transduced 
by these LVs. The VSV.G-LVs additionally transduced B 
and T cells which is expected as VSV.G is the envelope 
of choice for efficient transduction of a broad range of 
cells [37]. Of note, it has been postulated that targeting 
LVs would increase their transduction efficiency [38]. 
However, similar to the observations of Ageichik et al., 
who targeted LVs to MHC II-expressing cells [33], we 
observed a lower transduction efficiency with DC1.8- and 
DC2.1-LVs compared to VSV.G-LVs. In contrast, Yang 
et al. observed that LVs targeted to DC-SIGN were more 
efficient in transduction of CD11c+ cells than VSV.G-
LVs [39]. The latter might be explained by the type of 
antigen targeted, both in terms of its expression level 
and function. For instance, DC-SIGN is a C-type lectin, 
involved in the capture of HIV-1 and furthermore protects 
it from degradation in early endosomes [40]. The results 
from the in vivo bioluminescence imaging upon delivery 
of FLuc encoding LVs, support the notion that only short-
lived APCs are transduced by DC1.8- and DC2.1-LVs. As 
expected, the luminescence signal lasted for more than 20 
days after VSV.G-LV delivery, implying the transduction 
of long-lived, possibly non-APCs, which increases the risk 
of insertional mutagenesis [41].
Because DC1.8- and DC2.1-LVs deliver their cargo 
to different APC-subsets, we evaluated and compared their 
immunogenicity. It is generally accepted that cDCs within 
the LNs are required to present antigens to CD8+ T cells, 
while migrated DCs and pDCs are insufficient to prime 
T cells [42, 43]. Moreover within the cDC population it 
was found that the CD8alfa+ DEC205+ DC population 
surpasses other APC-subsets in cross-presenting skills 
[44–47]. Fuertes et al. further demonstrated that host 
type I IFNs are critical for the innate immune recognition 
of a growing tumor through signalling on the CD8alfa+ 
DC fraction [48]. In line with this observation, it was 
described that cDCs in a human setting need type I IFN 
and TNF-alfa, released from non-replicating HIV-1 
activated pDCs, to induce their full bystander maturation 
[49, 50]. Although cDCs seem to have a prominent role, 
the latter study stresses the importance of the pDCs. 
However, it was also shown in certain tumor models 
that tumor draining LN-resident pDCs expressed the 
enzyme indoleamine 2,3-dioxygenase, which induces 
the generation of regulatory T cells [51, 52]. The role 
of LN-resident macrophages in T cell stimulation is less 
defined. Although it was shown that CD8+ T cells interact 
with virally infected macrophages and DCs, macrophages 
were not shown to fully prime anti-viral CD8+ T cells 
[35]. Moreover, Albert et al. showed that human DCs 
but not macrophages efficiently presented antigens from 
apoptotic cells to CD8+ T cells [53]. Nonetheless, some 
studies report that macrophages can cross-prime CD8+ 
T cells [54]. In order to shed light on the importance 
of macrophages and pDCs in the stimulation of T cell 
responses, we evaluated the expansion of CD4+ and CD8+ 
T cells as well as their functionality upon immunization 
with DC1.8-, DC2.1- and VSV.G-LVs. Although 
immunization with VSV.G-LVs elicited stronger CD8+ T 
cell responses, we demonstrated that DC1.8- and DC2.1-
LVs were equally potent in the induction of CD8+ T cells 
with lytic and more importantly therapeutic efficacy. 
Interestingly, we observed that the induced CD4+ cytokine 
profile of DC2.1-LVs closely resembled that of VSV.G-
LVs as both elicited a similar amount of IFN-gamma, IL-2 
and IL-10. These cytokines are typical for a TH1 response 
and therefore crucial for a potent antitumor immune 
response. In contrast, DC1.8-LVs induced less of these 
cytokines while its profile resembled more that of the 
non-infectious BCII10 LVs, suggesting that presentation 
of antigens by cDCs alone is probably not as adequate as 
presentation by a broad range of APCs. Another striking 
observation was the complete abrogation of CTL inducing 
capacity of DC1.8- and DC2.1-LVs in IFNAR ko mice. 
The latter was unexpected, as it was described that pDCs 
and LN-resident macrophages are the main producers of 
type I IFNs upon LV transduction [35, 55]. Therefore, we 
only expected to observe a reduction in immunogenicity 
in IFNAR ko mice for VSV.G- and DC2.1-LVs. However, 
the immunogenicity of VSV.G-LVs was unaffected, 
whereas that of DC2.1- and DC1.8-LVs was compromised. 
The latter can in part be explained by our previous 
observations that LVs activate TLR3/7 and as such induce 
type I IFN production by DCs [17]. The ability of VSV.G-
LVs to elicit CTL responses in IFNAR ko mice suggests 
that these activate other innate pathways that are able to 
bypass the need for type I IFNs. The latter hypothesis was 
strengthened by the observation that VSV.G-LVs triggered 
the highest production of the pro-inflammatory cytokine 
TNF-alfa [49, 56].
Another surprise was the ability of the BCII10-
LVs to induce immune responses, despite their 
inability to transduce cells. The latter was explained 
by the presence of protein contaminants within the LV 
preparation and highlights the need for the development 
of easy to use and high efficiency LV-purification 
systems. Although, immunization with BCII10-LVs 
resulted in T cell responses, it is important to note that 
the CD4+ and CD8+ T cell responses upon immunization 
with infectious LVs were stronger. These observations 
are in line with the observations of Ageichik et al., 
who compared the induction of IFN-gamma+ CD8+ T 
cells upon administration of LVs targeted to MHC II or 
carcinoembryonic antigen [33]. However, in therapy, 
no striking differences were observed between BCII10-
, DC1.8-, DC2.1- and VSV.G-LVs. The latter has not 
been described but this could be explained by the fact 
that previous reports on the use of targeted LVs for anti-
cancer vaccination only compared LVs encoding the tumor 
antigen versus LVs encoding an irrelevant antigen [39, 
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57]. Importantly, studies using nanoparticles demonstrate 
that the strength of the immune responses induced is 
co-determined by the cell population that engulfs the 
particle as well as the cargo of these particles [58, 59]. 
We delivered the BCII10-LVs intranodally, which can 
be considered as an anatomical targeting of virus like 
particles [31]. It is therefore likely that BCII10-LVs have 
been engulfed by DCs and as such deliver proteins as well 
as viral components, ie activation signals which ultimately 
led to the induction of a small amount of TNF-alfa, IFN 
type I and IL-10.
In conclusion, we demonstrate that LV-
targeting to distinct DC-subsets via the Nb display 
technology is feasible and induces qualitatively distinct 
T cell responses that are equally potent in the control of 
cancer. Furthermore, this targeting strategy increases the 
LV-based vaccines’ safety through faster LV-clearance. 
In the future, experiments with tumor relevant antigens 
like MageA3, Trp2, p62 and brachyury, have to confirm 
the observed results with the egg white derived protein 
ovalbumin [60–63]. Furthermore the possible relief of side 
effects like vitiligo [64] with APC-targeted LVs has to be 
evaluated. Since we possess Nbs that target human cDCs 
alone [65] or human cDCs, pDCs and macrophages [23], 
this method represents a good option to produce LV-based 
vaccines for preclinical studies in cancer. 
MATERIALS AND METHODS 
Mice and cell cultures
Six to 12 week old female CD45.2+/Thy1.2+ 
C57BL/6 mice were purchased from Harlan. The 
CD45.1+/Thy1.2+ C57BL/6 mice were obtained from J. 
Van Ginderachter (Vrije Universiteit Brussel). Transgenic 
OT-I and OT-II mice were purchased from Charles River. 
Mice lacking the IFN type I receptor (IFNAR ko) were 
obtained from C. Libert (Universiteit Gent). All animals 
were handled according to the institutional guidelines and 
experiments were approved by the Ethical Committee for 
use of laboratory animals of the Vrije Universiteit Brussel. 
The human embryonal kidney 293T cell line (HEK293T) 
and T-cell lymphoma cell line E.G7-OVA were cultured as 
recommended by the American Type Culture Collection 
(ATCC). Single cell suspensions were prepared from 
spleens and lymph nodes (LNs) as described [23].
Lentiviral vector production
Plasmids. The packaging plasmid pCMVΔR8.9 and 
VSV.G encoding plasmid pMD.G were a gift from Dr. D. 
Trono (University of Geneva). The plasmid pUB6-VSV.
GS, which encodes the binding-defective, but fusion-
competent VSV.G was described by Zhang et al. [66]. 
The plasmids pSIN-Thy1.1, pHR trip CMV luc2-Ires-
tNGFR SIN, pHR’ trip CMV Ii80tOVA-Ires-tNGFR SIN, 
pcDNA1 Ii80tOVA, pHR’ trip CMV Nb BCII10 SIN and 
pHR’ trip CMV Nb DC2.1 SIN were described [17, 23, 28, 
67]. The sequence encoding the membrane bound form of 
Nb DC1.8 was cloned into the pHR’ trip CMV SIN vector 
following the same strategy as described for Nb BCII10 
and DC2.1 [23].
Virus production and characterization. Production 
of broad tropism and targeted LVs as well as their 
characterization was performed as described [23]. 
In vivo bioluminescence imaging 
In vivo bioluminescence imaging was performed at 
the indicated time points to visualize in situ transduction 
of cells after intranodal delivery of 10E6 transducing 
units (TUs) of FLuc encoding LVs. The procedure was 
performed as described [68].
In vivo tracking of lentivirally transduced cells
To evaluate the transduction profile of the LVs, 
C57BL/6 mice were injected in the inguinal LN with 
10E6 TUs of Thy1.1 encoding LVs. Thirty-six hours later, 
mice were euthanized, injected LNs isolated, single cell 
suspensions prepared and cells characterized by flow 
cytometry [23].
In vivo OT-I and OT-II stimulation with ELISA 
on restimulated OT-II cells
One day prior to immunization, 1-2 x 10E6 purified 
and carboxyfluorescein diacetate succinimidine ester 
(CFSE, Invitrogen) labeled CD8+ OT-I or CD4+ OT-
II spleen cells were adoptively transferred to mice by 
intravenous injection. Mice were immunized through 
single administration of 5 x 10E5 TUs of broad tropism or 
Nb-targeted LVs encoding ovalbumin into the inguinal LN. 
Administration of PBS or BCII10-LVs served as a control. 
Five days post-immunization, proliferation of T cells 
was analyzed. Therefore, LNs were isolated, single cell 
suspensions prepared, stained with a peridinin-chlorophyll 
protein-Cy5.5 (PerCP-Cy5.5) conjugated antibody against 
CD8 or CD4 (BD) and analyzed via flow cytometry as 
described [20]. When mice were adoptively transferred 
with OT-II cells, part of the single cell suspensions were 
used to sort and restimulate the CD4+ T cells. Therefore, 
5 x 10E5 of CD4+ T cells were plated in a 48-well plate in 
500 µl of culture medium and restimulated for 48 hours 
with bone marrow-derived DCs that were loaded for two 
hours with 5 μM ISQAVHAAHAEINEAGR peptide 
(Eurogentec) at a 10:1 ratio. Supernatants were screened 
in enzyme-linked immunosorbent assay (ELISA) for the 
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presence of IFN-gamma, IL-2, IL-17, IL-4 and IL-10 
(eBioscience). 
Intracytoplasmic staining of IFN-gamma
One day prior to immunization, CD45.1+ C57BL/6 
mice were injected with 5 x 10E6 CD45.2+ OT-I cells. 
Mice were immunized as described above. Five days 
post-immunization, spleens and LNs were isolated and 
CD45.2+ OT-I cells sorted using anti-CD45.2 beads 
(Miltenyi). Subsequently, 5 x 10E5 of these cells were 
plated in a 48-well plate in 500 µl of RPMI+ (RPMI-1640 
medium supplemented with 5% FCI, 5% supplements 
and 50 μmol/L β-mercaptoethanol) and restimulated with 
SIINFEKL loaded CD45.1 splenocytes at a 10:1 ratio. 
Two days later Golgi plug was added (1mg/ml, BD) and 
intracytoplasmic expression of IFN-gamma was evaluated 
the next day by intracellular staining with a phycoerythrin-
Cy7 (PE-Cy7) conjugated anti-IFN-gamma antibody 
(eBioscience) followed by flow cytometric analysis. 
In vivo cytotoxic T lymphocyte assay
Mice were immunized through intranodal 
administration of 5 x 10E5 TUs of broad tropism or 
targeted ovalbumin encoding LVs. Administration of PBS 
or BCII10-LVs served as a control. The in vivo cytotoxicity 
assay was performed five days post-immunization as 
described [20].
Evaluation of TNF-alfa secretion after intranodal 
immunization
Mice were injected intranodally with 5 x 10E5 TUs 
of broad tropism or targeted ovalbumin encoding LVs. No 
injection, PBS or BCII10-LVs served as control. Three 
hours later, LNs were resected and transferred to a 24-
well plate with 300 µl of RPMI+. Twenty hours later, 
supernatants were screened in ELISA for the presence of 
TNF-alfa (eBioscience). 
Flow cytometry
Staining of surface markers was performed as 
described [23]. Data were collected using a FACS Canto 
flow cytometer (BD) and analyzed using FACSDivaTM 
(BD) or FlowJoTM (Tristar Inc.) software.
Tumor rejection experiments
Mice were grafted subcutaneously with 3 x 10E5 
E.G7-OVA tumor cells at the tail base. Mice bearing 
palpable tumors were immunized twice with 10E6 TUs of 
LVs encoding ovalbumin at a seven-day interval. Tumor 
growth was monitored. Mice were killed when the tumor 
reached a volume of 2500 mm3.
Statistical analyses
A one-way ANOVA followed by a Bonferroni’s 
multiple comparison test was performed. Sample sizes 
and number of times experiments were repeated are 
indicated in the figure legends. Number of asterisks in 
the figures indicates the level of statistical significance as 
follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001. The 
results are shown in a column graph or table as the mean 
± SEM. Survival was visualized in a Kaplan-Meier plot. 
Differences in survival were analyzed by the log-rank test.
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